Showing results (1-10 of 1,901) with videos related to

Sort By:
Pageof 191
Memo|April 3, 2018
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients: Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancerIrene Resch, Shahrokh F Shariat, Kilian M Gust
Current Opinion in Urology|April 3, 2020
Frontiers in combining immune checkpoint inhibitors for advanced urothelial cancer managementKatharina Rebhan, Ekaterina Laukhtina, Shahrokh F Shariat, et al.
Translational Andrology and Urology|November 22, 2021
Update on systemic treatment of upper tract urothelial carcinoma: a narrative review of the literatureKilian M Gust, Irene Resch, David D'Andrea, et al.
Current Opinion in Urology|May 27, 2020
Immune checkpoint inhibition in muscle-invasive and locally advanced bladder cancerKilian M Gust, Katharina Rebhan, Irene Resch, et al.
Urologic Oncology|April 25, 2018
A systematic review and meta-analysis of lymphovascular invasion in patients treated with radical cystectomy for bladder cancerAndrea Mari, Shoji Kimura, Beat Foerster, et al.
World Journal of Urology|June 28, 2018
Molecularly-driven precision medicine for advanced bladder cancerLaura-Maria Krabbe, Vitaly Margulis, Andres Jan Schrader, et al.
BJU International|January 18, 2019
Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancerDavid D'Andrea, Francesco Soria, Sonja Zehetmayer, et al.
World Journal of Urology|March 18, 2018
Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancerFrancesco Soria, Andrea I Beleni, David D'Andrea, et al.
Translational Andrology and Urology|October 28, 2016
Predictive models and prognostic factors for upper tract urothelial carcinoma: a comprehensive review of the literatureAurélie Mbeutcha, Romain Mathieu, Morgan Rouprêt, et al.
Anticancer Research|October 7, 2017
ABO Blood Group and Rhesus Factor Are Not Associated with Outcomes After Radical Cystectomy for Non-metastatic Urothelial Carcinoma of the BladderDavid D'Andrea, Marco Moschini, Francesco Soria, et al.
Pageof 191